{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.2","spread":"20.2","upperLimit":"27.9","value":"24.1"},{"groupId":"OG001","lowerLimit":"6.6","spread":"6.6","upperLimit":"11.8","value":"9.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"478"},{"groupId":"OG001","value":"476"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG000","title":"Lenvatinib"},{"description":"Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG001","title":"Sorafenib"}],"paramType":"NUMBER","populationDescription":"The FAS included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}